“…Induction therapy with infliximab significantly improved the HRQOL of patients with severe plaque psoriasis. Patients who participated in the study had baseline DLQI scores that were similar to 18,19 or worse than 20 those of patients participating in other studies of therapy for psoriasis. After receiving only three doses of infliximab, patients reported a significant reduction in the impact of psoriasis on all aspects of HRQOL assessed by DLQI, including daily activities, social functioning, personal relationships, and work or study.…”